MARKET
IPO

INAI

Invea Therapeutics, Inc.
INAI
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-02-05
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-2.44~-2.04
-
-
99.77M~119.72M
Biotechnology & Medical Research
2026-01-28
Public Filing
View Prospectus
2026-01-28
Offering
Price Range: 10.00~12.00
Shares to be Issued: 3200.00K
2026-02-04
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 9976.77K
2026-02-05
Listed
No Data
About INAI
Invea Therapeutics Inc. is a biotechnology company, which is engaged in developing small molecule oral therapeutics for immune-mediated inflammatory diseases (IMIDs). The Company’s product candidates include INVA8001 and INVA8003. The Company’s lead product candidate, INVA8001, is an oral, small-molecule, highly selective, and potent chymase inhibitor designed to target mast cell-driven inflammation in immune-mediated inflammatory diseases. The Company’s second product candidate, INVA8003, is a novel oral small-molecule inhibitor of apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), an adaptor protein that facilitates the assembly and activation of various inflammasomes, which are key mediators that drive inflammatory responses and cell death. Its product candidates are identified using the AlphaMeld Platform, a technology-enabled drug discovery platform.

Webull offers Invea Therapeutics, Inc. stock information, including NASDAQ: INAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAI stock methods without spending real money on the virtual paper trading platform.